Key statistics
As of last trade Summit Therapeutics Inc (SMMT*:MEX) traded at 374.00, -13.02% below its 52-week high of 430.00, set on Oct 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 375.00 |
---|---|
High | 375.00 |
Low | 374.00 |
Bid | 373.00 |
Offer | -- |
Previous close | 374.00 |
Average volume | -- |
---|---|
Shares outstanding | 737.45m |
Free float | 115.30m |
P/E (TTM) | -- |
Market cap | 13.58bn USD |
EPS (TTM) | -0.2768 USD |
Data delayed at least 20 minutes, as of Oct 31 2024 15:13 BST.
More ▼
Press releases
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
- PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
- Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
- Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
- PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
- Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
- Summit Therapeutics Raises $235 Million
- Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
More ▼